Ambroxol Hydrochloride

DRUG6 trials

Sponsors

Hull University Teaching Hospitals NHS Trust, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, National University of Malaysia, University Medical Center Groningen

Conditions

Community-acquired PneumoniaCoughCritical IllnessGBA Gene MutationHospital-acquired PneumoniaLewy Body DiseaseParkinsonParkinson Disease

Phase 1

Ambroxol as a Novel Disease Modifying Treatment for Lewy Body Dementia

Not yet recruitingNCT04405596

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sLewy Body Disease

Start: 2025-01-31End: 2027-01-31Target: 15Updated: 2023-12-13

High-Dose Ambroxol in GBA1-Related Parkinson

RecruitingNCT06193421

Agyany Pharma LTDGBA Gene Mutation, Parkinson Disease

Start: 2023-10-24End: 2025-04-30Target: 40Updated: 2024-02-08

Phase 2

A Study of the Effect of 20 mg Ambroxol Hydrochloride on Acute Cough.

CompletedNCT03415269

Hull University Teaching Hospitals NHS TrustCough

Start: 2018-02-15End: 2018-04-19Updated: 2019-06-20

Ambroxol as a Disease-modifying Treatment in GBA-PD

CompletedNCT05287503

Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaGBA Gene Mutation, Parkinson Disease

Start: 2022-03-09End: 2024-12-20Updated: 2025-08-14

GRoningen Early-PD Ambroxol Treatment

University Medical Center GroningenParkinson, Parkinson Disease

Start: 2023-05-31End: 2025-07-31Target: 80Updated: 2023-05-10

Phase 4

Efficacy of Intravenous Amboxol Hydrochloride as an Adjunct Therapy for Severe Pneumonia in Critically Ill Patients

CompletedNCT05663905

National University of MalaysiaCommunity-acquired Pneumonia, Critical Illness, Hospital-acquired Pneumonia +1

Start: 2023-01-07End: 2023-10-31Updated: 2023-12-27

Related Papers

Study protocol of the GRoningen early-PD Ambroxol treatment (GREAT) trial: a randomized, double-blind, placebo-controlled, single center trial with ambroxol in Parkinson patients with a GBA mutation.

2024-05-018 citations

Ambroxol as a disease-modifying treatment to reduce the risk of cognitive impairment in <i>GBA</i>-associated Parkinson’s disease: a multicentre, randomised, double-blind, placebo-controlled, phase II trial. The AMBITIOUS study protocol

BMJ Neurology Open2023-11-0126 citations